Results 161 to 170 of about 62,762 (312)

Estetrol-based combined oral contraceptives: A systematic review of clinical outcomes. [PDF]

Acta Obstet Gynecol Scand
Råberg M, Vad IR, Axelsdóttir KH, Løkkegaard ECL.   +3 more
europepmc   +1 more source

Oral Contraceptives: The Risks, Benefits, and Dilemmas

, 2010
Millions of women have chosen to use oral contraceptives for various reasons. However, the question must be raised as to the awareness level of the risks and benefits associated with the use of oral contraceptives.
West, Courtney S
core  

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Prevalência de uso de métodos contraceptivos e adequação do uso de anticoncepcionais orais na cidade de Pelotas, Rio Grande do Sul, Brasil

Cadernos de Saúde Pública
Através de um inquérito de prevalência de base populacional entre mulheres de 20 a 49 anos, residentes na zona urbana da cidade de Pelotas, Rio Grande do Sul, estudou-se o consumo de métodos contraceptivos. Entre as 677 mulheres, verificou-se que 455 (65,
Juvenal Soares Dias da Costa, Paula Berenhauser D'Elia, Mônica Regina Moreira   +2 more
doaj  

Comparison of Dermatologic and Neuropsychological Side Effects of Oral Contraceptives, 2016-2020. [PDF]

Open Access J Contracept
Visingardi J, Feustel PJ, Flink-Bochacki R, Denefrio C.   +3 more
europepmc   +1 more source

Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing

Drug Testing and Analysis, EarlyView.
Results confirm that the MRL of 30 ng/mL for 21‐desacetyl‐deflazacort together with a 3‐day washout period is an appropriated strategy to detect oral deflazacort administration in sport competition. ABSTRACT Deflazacort (DEF) is a glucocorticoid prohibited in sports competitions when orally administered.
Sergi Coll, Claudia Bressan, Núria Monfort, Ana Aldea‐Perona, Marcel·lí Carbó, Rosa Ventura   +5 more
wiley   +1 more source

Combined Oral Contraceptives and the Risk of Thrombosis. [PDF]

Int J Mol Sci
Khizroeva J, Bitsadze V, Sukhikh G, Tretyakova M, Gris JC, Elalamy I, Gerotziafas G, Kapanadze D, Kvaratskheliia M, Tatarintseva A, Khisamieva A, Hovancev I, Yakubova F, Makatsariya A.   +13 more
europepmc   +1 more source

Daily Ovarian Hormone Exposure and Loss of Control Eating in Adolescent Girls: A Stage 2 Registered Report

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This Stage 2 Registered Report examined (1) the main effects and interaction of within‐person daily associations between ovarian hormones (i.e., estrogen, progesterone) and loss of control eating (LOCE), and (2) the within‐person mediating roles of food‐related reward anticipation and response inhibition. Methods Adolescent girls (n =
Tyler B. Mason, Jeremy C. Morales, Kathryn E. Smith, Genevieve F. Dunton, Raina D. Pang   +4 more
wiley   +1 more source

Do combined oral contraceptives induce formation of tissue factor? [PDF]

Res Pract Thromb Haemost
Kristensen SR, Nybo J, Strandberg J.
europepmc   +1 more source

Reply : oral contraceptives and bone mineral density

, 2001
Reply : oral contraceptives and bone mineral ...
Julie Pasco (13077054), G Nicholson (9895088), M Kotowicz (13731730)   +2 more
core